Protagonist Therapeutics
PTGX
121.40
-2.62
-2.11%
Protagonist Therapeutics
US · PTGX
#1570 by market cap
Listed 2016
121.40
-2.62
-2.11%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Rating change
H.C. Wainwright Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $170Market Newswire · 2026/8/31
-
Rating change
A Quick Look at Today's Ratings for Protagonist Therapeutics(PTGX.US), With a Forecast Between $149 to $182Market Newswire · 2026/9/1
-
BMO Capital Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $190Market Newswire · 2026/11/11
-
Wedbush Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $173Market Newswire · 2026/11/10
-
Rating change
BMO Capital Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $178Market Newswire · 2026/8/17
-
Rating change
A Quick Look at Today's Ratings for Protagonist Therapeutics(PTGX.US), With a Forecast Between $167 to $186Market Newswire · 2026/8/11
-
UBS Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $184Market Newswire · 2026/11/10
-
Rating change
Barclays Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $180Market Newswire · 2026/11/6
-
Rating change
UBS Initiates Protagonist Therapeutics(PTGX.US) With Buy Rating, Announces Target Price $184Market Newswire · 2026/10/12
-
Rating change
J.P. Morgan Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $149Market Newswire · 2026/9/1
-
Rating change
Truist Financial Maintains Protagonist Therapeutics(PTGX.US) With Buy RatingMarket Newswire · 2026/9/2
-
Rating change
Citi Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $182Market Newswire · 2026/10/15
-
Rating change
H.C. Wainwright Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $170Market Newswire · 2026/9/1
-
Rating change
BMO Capital Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $190Market Newswire · 2026/11/6
-
H.C. Wainwright Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $221Market Newswire · 2026/11/6
-
Rating change
TD Cowen Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $160Market Newswire · 2026/10/21
-
Rating change
Goldman Sachs Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $186Market Newswire · 2026/9/1
-
Rating change
J.P. Morgan Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $149Market Newswire · 2026/8/13
-
Rating change
BMO Capital Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $178Market Newswire · 2026/8/31
-
J.P. Morgan Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $151Market Newswire · 2026/11/9
-
Rating change
Wedbush Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $173Market Newswire · 2026/8/31
-
Barclays Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $180Market Newswire · 2026/10/13
-
Rating change
Goldman Sachs Upgrades Protagonist Therapeutics(PTGX.US) to Buy Rating, Raises Target Price to $186Market Newswire · 2026/8/10
-
Rating change
Wedbush Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $173Market Newswire · 2026/8/10
-
Rating change
A Quick Look at Today's Ratings for Protagonist Therapeutics(PTGX.US), With a Forecast Between $153 to $175Market Newswire · 2026/8/7
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Protagonist Therapeutics discussion 0 comments